Bionano Genomics Valuation
| BNGO Stock | USD 0.42 0.02 5.00% |
Bionano Genomics is undervalued. Bionano Genomics shows a prevailing Real Value of $3.61 per share. The current price of the firm is $0.42. Our model approximates the value of Bionano Genomics from analyzing the firm fundamentals such as Return On Equity of -1.38, shares outstanding of 86 M, and Operating Margin of (2.03) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Bionano Genomics' valuation include:
Price Book 0.4541 | Enterprise Value 45.1 M | Enterprise Value Ebitda (0.18) | Price Sales 0.9874 | Trailing PE 0.0425 |
Undervalued
Today
Please note that Bionano Genomics' price fluctuation is very risky at this time. Calculation of the real value of Bionano Genomics is based on 3 months time horizon. Increasing Bionano Genomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bionano Genomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bionano Stock. However, Bionano Genomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.42 | Real 3.61 | Target 13.2 | Hype 0.39 | Naive 0.36 |
The intrinsic value of Bionano Genomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bionano Genomics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bionano Genomics helps investors to forecast how Bionano stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bionano Genomics more accurately as focusing exclusively on Bionano Genomics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Bionano Genomics' intrinsic value based on its ongoing forecasts of Bionano Genomics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Bionano Genomics' closest peers.
Bionano Genomics Cash |
|
Bionano Valuation Trend
Knowing Bionano Genomics' actual value is paramount for traders when making sound investment determinations. Using both Bionano Genomics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Bionano Genomics Total Value Analysis
Bionano Genomics is currently forecasted to have valuation of 45.11 M with market capitalization of 36.12 M, debt of 87.95 M, and cash on hands of 187.34 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Bionano Genomics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
45.11 M | 36.12 M | 87.95 M | 187.34 M |
Bionano Genomics Investor Information
The company has price-to-book (P/B) ratio of 0.45. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bionano Genomics recorded earning per share (EPS) of 9.89. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 7th of August 2023. Based on the key indicators related to Bionano Genomics' liquidity, profitability, solvency, and operating efficiency, Bionano Genomics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in October.Bionano Genomics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bionano Genomics has an asset utilization ratio of 16.84 percent. This suggests that the Company is making $0.17 for each dollar of assets. An increasing asset utilization means that Bionano Genomics is more efficient with each dollar of assets it utilizes for everyday operations.Bionano Genomics Ownership Allocation
Bionano Genomics holds a total of 86 Million outstanding shares. Almost 88.12 percent of Bionano Genomics outstanding shares are held by general public with 0.12 (percent) owned by insiders and only 11.76 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Bionano Genomics Profitability Analysis
The company reported the previous year's revenue of 36.12 M. Net Loss for the year was (232.49 M) with profit before overhead, payroll, taxes, and interest of 5.95 M.About Bionano Genomics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Bionano Genomics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Bionano Genomics based exclusively on its fundamental and basic technical indicators. By analyzing Bionano Genomics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Bionano Genomics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bionano Genomics. We calculate exposure to Bionano Genomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bionano Genomics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 9.6 M | 4.9 M | |
| Pretax Profit Margin | (6.44) | (6.76) | |
| Operating Profit Margin | (3.86) | (4.05) | |
| Net Loss | (6.44) | (6.76) | |
| Gross Profit Margin | 0.26 | 0.34 |
Bionano Genomics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 34.1 M |
Bionano Genomics Current Valuation Indicators
Valuation refers to the process of determining the present value of Bionano Genomics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Bionano we look at many different elements of the entity such as Bionano's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Bionano Genomics' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Bionano Genomics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Bionano Genomics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Bionano Genomics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Bionano Genomics' worth.Additional Information and Resources on Investing in Bionano Stock
When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 9.89 | Revenue Per Share 0.749 | Quarterly Revenue Growth (0.10) | Return On Assets (0.33) | Return On Equity (1.38) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.